Zhitong Finance App News, Yasheng Pharmaceutical (06855.HK) announced that several of the company's clinical and preclinical research advances were selected for the 68th American Society of Hematology (ASH) Annual Meeting, involving the first third-generation BCR-ABL inhibitor approved for marketing in China olevatinib (trade name: Nelick®), the first domestically produced original BCl-2 inhibitor approved for marketing in China (trade name: Risheng®), and the PRC2/EED inhibitor APG-5918 The four varieties of BTK degrading agent APG-3288 fully demonstrate the company's deep layout and global innovation strength in the field of hematologic oncology. It is worth noting that APG-5918 first published clinical data and received an oral report.

Zhitongcaijing · 3d ago
Zhitong Finance App News, Yasheng Pharmaceutical (06855.HK) announced that several of the company's clinical and preclinical research advances were selected for the 68th American Society of Hematology (ASH) Annual Meeting, involving the first third-generation BCR-ABL inhibitor approved for marketing in China olevatinib (trade name: Nelick®), the first domestically produced original BCl-2 inhibitor approved for marketing in China (trade name: Risheng®), and the PRC2/EED inhibitor APG-5918 The four varieties of BTK degrading agent APG-3288 fully demonstrate the company's deep layout and global innovation strength in the field of hematologic oncology. It is worth noting that APG-5918 first published clinical data and received an oral report.